Sign In
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
New Delhi: Sudeep Pharma IPO, a book build issue of Rs 895 crore, got fully subscribed on the first day of share sale on November 21, 2025. The initial public offer opened for subscription on Friday and will close on 24 November. As per the NSE data, the mainboard IPO received bids for 1,50,09,425 shares, while 1,05,64,926 shares are up for grabs. Non-Institutional Investors received 3 times the subscription, while the quota for Retail Individual Investors (RIIs) fetched 1.50 times subscription, and the Qualified Institutional Buyers (QIBs) attracted 9 per cent subscription.
As per investorgain, Sudeep Pharma IPO GMP stood at Rs 112 in the morning of November 24, 2025. With the price band of Rs 593, the shares are expectdd to be listed at rs 705 apiece, indicating a gain of nearly 19 per cent.
Sudeep Pharma IPO price band is fixed in the range of Rs 563 to Rs 593 per share. The Sudeep Pharma IPO allotment is expected to be finalised on November 26, 2025. The shares will list on BSE, NSE with a tentative listing date fixed as 28 November.
Retail investors are required to bid for a minimum lot of 25 shares, for which minimum amount of investment required is Rs 14,825. The investors applying in the NII category, are mandated to bid for a minimum of 14 lots, and for bNII, it is 68 lots.
The issue is a combination of fresh issue of 0.16 crore shares comprising a fresh issue of equity shares worth Rs 95 crore and an offer-for-sale of nearly 1.35 crore equity shares, aggregating to Rs 800 crore, by the promoters.
In its papers filed with SEBI, Proceeds from the IPO to the tune of Rs 75.81 crore will be used for capital expenditure towards the procurement of machinery for its production line located at the Nandesari Facility 1, Gujarat, and for general corporate purposes.
Sudeep Pharma is engaged in the business of a technology-led manufacturer of excipients and speciality ingredients for the pharmaceutical, food, and nutrition industries, dedicated to contributing to the global healthcare ecosystem.
(Disclaimer: This article is only meant to provide information. TV9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, gold, silver and crypto assets.)
